[HTML][HTML] A guide to immunotherapy for COVID-19

FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …

COVID-19 therapeutics: Challenges and directions for the future

PC Robinson, DFL Liew, HL Tanner… - Proceedings of the …, 2022 - National Acad Sciences
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

[PDF][PDF] Therapeutics and COVID-19: living guideline, 13 January 2023

World Health Organization - 2023 - apps.who.int
As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …

[HTML][HTML] The development of COVID-19 treatment

Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among …

S Mazloomzadeh, S Khaleghparast, B Ghadrdoost… - Jama, 2021 - jamanetwork.com
Importance Thrombotic events are commonly reported in critically ill patients with COVID-19.
Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate …

[HTML][HTML] Inflammasome activation at the crux of severe COVID-19

SM Vora, J Lieberman, H Wu - Nature Reviews Immunology, 2021 - nature.com
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), results in life-threatening disease in a minority of patients, especially elderly …

Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 …

L Russell, KR Uhre, ALS Lindgaard, JF Degn… - Jama, 2021 - jamanetwork.com
Importance A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in
patients with severe and critical COVID-19, but a higher dose may benefit those with more …

[HTML][HTML] COVID-19 and diabetes mellitus: from pathophysiology to clinical management

S Lim, JH Bae, HS Kwon, MA Nauck - Nature Reviews Endocrinology, 2021 - nature.com
Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …

COVID-19 and cardiovascular disease: from bench to bedside

MK Chung, DA Zidar, MR Bristow, SJ Cameron… - Circulation …, 2021 - Am Heart Assoc
A pandemic of historic impact, coronavirus disease 2019 (COVID-19) has potential
consequences on the cardiovascular health of millions of people who survive infection …

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

JAC Sterne, S Murthy, JV Diaz, AS Slutsky, J Villar… - Jama, 2020 - jamanetwork.com
Importance Effective therapies for patients with coronavirus disease 2019 (COVID-19) are
needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced …